Observational studyInternational journal of molecular sciences2016
EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.
Observational study in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- KRASFrontiers in oncology · 2026Pooled it
- Pooled it
- Evaluating the efficacy of G12C inhibitors in conjunction with Gamma Knife radiosurgery for KRAS-mutant non-small cell lung cancer brain metastases.Journal of neuro-oncology · 2026Article
- Incidence and prognosis of brain metastases in esophageal carcinoma: a systematic review and meta-analysis.Journal of thoracic disease · 2025Article
- Single Pontine Relapse Shortly After Hippocampal Avoidance Whole Brain Radiotherapy: A Case Report.Cancer reports (Hoboken, N.J.) · 2025Article
- Intracranial Disease Control and Survival among Patients with KRAS-mutant Lung Adenocarcinoma and Brain Metastases Treated with Stereotactic Radiosurgery.International journal of radiation oncology, biology, physics · 2025Article
- Breaking boundaries: role of the brain barriers in metastatic process.Fluids and barriers of the CNS · 2025Review
- Different genetic profiles contribute to worse overall survival in patients with leptomeningeal metastases of non-small-cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Liquid biopsy for evaluating mutations and chromosomal aberrations in cerebrospinal fluid from patients with primary or metastatic CNS tumors.The journal of liquid biopsy · 2024Article
- Prognosis versus Actual Outcomes in Stereotactic Radiosurgery of Brain Metastases: Reliability of Common Prognostic Parameters and Indices.Current oncology (Toronto, Ont.) · 2024Article
- Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.Scientific reports · 2024Article
- Safety and Intracranial Activity of Adagrasib in Patients WithJCO precision oncology · 2024Article
- Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy.Drug design, development and therapy · 2024Review
- Resistance to KRAS inhibition in advanced non-small cell lung cancer.Frontiers in oncology · 2024Review
- Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain-only relapse versus synchronous extracranial relapse.Cancer medicine · 2023Article
- Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase (Translational lung cancer research · 2023Review
- The number of brain metastases predicts the survival of non-small cell lung cancer patients with EGFR mutation status.Cancer reports (Hoboken, N.J.) · 2022Article
- Machine learning application in personalised lung cancer recurrence and survivability prediction.Computational and structural biotechnology journal · 2022Article
- A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib.Lung Cancer (Auckland, N.Z.) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is the leading cause of brain metastases (BM). The identification of driver oncogenes and matched targeted therapies has improved outcome in non-small cell lung cancer (NSCLC) patients; however, a better understanding of BM molecular biology is needed to further drive the process in this field.
methodsIn this observational study, stage IV NSCLC patients tested for
resultsA total of 144 patients (142 Caucasian and two Asian) were selected, including 11.27% with
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.